Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02231203
Other study ID # NL46230.029.13
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 2014
Est. completion date June 2016

Study information

Verified date July 2018
Source Medical Center Alkmaar
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ideally, the postoperative inflammatory response is part of a well-orchestrated mechanism that contributes to tissue healing and rapid recovery. An exaggerated uncontrolled inflammatory response, however may lead to catabolism, tissue damage and organ failure. Omega-3 fatty acids may provide a means to alter cellular immune responses to the benefit of the patient. When omega-3 fatty acids are incorporated into membranes of inflammatory cells, they trigger intracellular signalling pathways that result in a less pro-inflammatory response. They modify gene and protein expression, modulate membrane protein activity and act as a reservoir for bioactive molecules. They also have a strong anti-inflammatory effect by mediating resolution of the inflammation. Furthermore, omega-3 fatty acids improve erythrocyte function, which is vital for an adequate microcirculation, tissue oxygenation and wound healing.

The investigators hypothesize that the perioperative administration of intravenous omega-3 fatty acids results in a rapid incorporation in immune cells and erythrocytes, thereby reducing the postoperative inflammatory response and improving erythrocyte function in patients undergoing colorectal surgery.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients (male or female) undergoing elective laparoscopic surgery for colon cancer

- Age between 60 and 80 years

- BMI between 20 kg/m2 and below 30 kg/m2

- Written informed consent

Exclusion Criteria:

- Participation in or having participated in another clinical trial within the previous 3 months

- Indications for continuously use of anticoagulant medication and no possibility to stop these medication perioperatively, for example patients with an artificial heart valve

- Pre-operative Hemoglobin<5.0 mmol/L

- Metastatic disease

- Very poor peripheral venous access

- Current history of inflammatory or infectious disease

- The use of anti-inflammatory drugs

- The use of thyroid medication

- The use of fish oil products or fish consumption more than 2 times a week

- Contra-indication for the use of Omegaven-Fresenius, including:

- General contra-indications for parenteral nutrition

- Allergy to fish or egg protein.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Omegaven
2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Placebo
2 infusions, 2 ml/kg, one the night before operation and one the day after operation

Locations

Country Name City State
Netherlands Medical Center of Alkmaar Alkmaar Noord Holland

Sponsors (1)

Lead Sponsor Collaborator
Medical Center Alkmaar

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Postoperative outcome (composite measure of length of stay and complications) Length of hospital stay and occurence of surgical site infection, abscess, urinary tract infection, pneumonia, anastomotic leakage, need for Intensive Care Unit admission, Systemic Inflammatory Response Syndrome, Multi Organ Failure, any adverse events. Registration during admission, follow up 2 and 4 weeks after surgery
Other Cognitive function Neuropsychological examination using a reading test, an auditory verbal learning test, WAIS III figure series and trail making tests. baseline, follow up 2 weeks after surgery
Primary Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood Ex vivo stimulation of whole blood with LPS (lipopolysaccharide, component of gram negative bacteria) resulting in the production of the pro-inflammatory cytokine IL-6, measured in ng/ml. baseline, day of surgery, postoperative day 1,2 and 4
Secondary Change in ex vivo production of TNF-a and IL-10 in LPS stimulated whole blood Ex vivo stimulation of whole blood with LPS (lipopolysaccharide, component of gram negative bacteria) resulting in the production of the pro-inflammatory cytokine TNF-a (tumor necrosis factor-a), and the anti-inflammatory cytokine IL-10 (interleukine-10), both measured in ng/ml. baseline, day of surgery, postoperative day 1, 2 and 4
Secondary Change in erythrocyte function Erythrocyte deformability and aggregation measured by LORRCA (laser assisted optical rotational red cell analyzer) baseline, day of surgery, postoperative day 1, 2 and 4
Secondary Change in in vivo systemic inflammatory response parameters White blood cell count, C-reactive protein and cytokine levels (Interleukine-6, Tumor Necrosis Factor-a and Interleukine-10) in serum. baseline, day of surgery, postoperative day 1, 2 and 4
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT03457454 - Reducing Rural Colon Cancer Disparities
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Completed NCT03390907 - Hybrid APC Assisted EMR for Large Colon Polyps N/A
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT04079478 - The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
Active, not recruiting NCT04057274 - Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth N/A
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Not yet recruiting NCT05147545 - Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects N/A
Recruiting NCT05026268 - The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis N/A
Not yet recruiting NCT03277235 - Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients N/A
Active, not recruiting NCT02959541 - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer N/A
Active, not recruiting NCT02730702 - Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02577627 - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC N/A
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Recruiting NCT02526836 - Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer Phase 2/Phase 3